1. Home
  2. COHN vs LEXX Comparison

COHN vs LEXX Comparison

Compare COHN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COHN
  • LEXX
  • Stock Information
  • Founded
  • COHN 1999
  • LEXX 2004
  • Country
  • COHN United States
  • LEXX Canada
  • Employees
  • COHN N/A
  • LEXX N/A
  • Industry
  • COHN Investment Bankers/Brokers/Service
  • LEXX Biotechnology: Pharmaceutical Preparations
  • Sector
  • COHN Finance
  • LEXX Health Care
  • Exchange
  • COHN Nasdaq
  • LEXX Nasdaq
  • Market Cap
  • COHN 21.6M
  • LEXX 19.6M
  • IPO Year
  • COHN N/A
  • LEXX N/A
  • Fundamental
  • Price
  • COHN $11.83
  • LEXX $0.98
  • Analyst Decision
  • COHN
  • LEXX Strong Buy
  • Analyst Count
  • COHN 0
  • LEXX 1
  • Target Price
  • COHN N/A
  • LEXX $5.00
  • AVG Volume (30 Days)
  • COHN 8.9K
  • LEXX 138.5K
  • Earning Date
  • COHN 08-04-2025
  • LEXX 07-14-2025
  • Dividend Yield
  • COHN 8.45%
  • LEXX N/A
  • EPS Growth
  • COHN N/A
  • LEXX N/A
  • EPS
  • COHN N/A
  • LEXX N/A
  • Revenue
  • COHN $84,171,000.00
  • LEXX $615,923.00
  • Revenue This Year
  • COHN N/A
  • LEXX $6.04
  • Revenue Next Year
  • COHN N/A
  • LEXX $8.36
  • P/E Ratio
  • COHN N/A
  • LEXX N/A
  • Revenue Growth
  • COHN N/A
  • LEXX 49.85
  • 52 Week Low
  • COHN $6.10
  • LEXX $0.79
  • 52 Week High
  • COHN $13.25
  • LEXX $4.38
  • Technical
  • Relative Strength Index (RSI)
  • COHN 75.00
  • LEXX 55.13
  • Support Level
  • COHN $11.00
  • LEXX $0.82
  • Resistance Level
  • COHN $13.25
  • LEXX $1.05
  • Average True Range (ATR)
  • COHN 0.45
  • LEXX 0.06
  • MACD
  • COHN 0.12
  • LEXX 0.02
  • Stochastic Oscillator
  • COHN 54.19
  • LEXX 70.77

About COHN Cohen & Company Inc.

Cohen & Co Inc is a United States company that delivers financial services in fixed-income markets. It is focused on small-cap banking institutions and has grown to provide an expanding range of capital markets and asset management services. It has three business segments. The Capital Markets segment, which is the key revenue driver, consists of fixed-income sales, trading, matched book repo financing, new issue placements in corporate and securitized products, and advisory services. The Asset Management segment manages assets within collateralized debt obligations, managed accounts, joint ventures, and investment funds. The Principal Investing segment is comprised of investments to earn return rather than to support trading, matched book repo, or other Capital Markets segment activities.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: